• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

A prognostic scoring system for patients with multiple myeloma classified as stage II with the Revised International Staging System.

作者信息

Jung Sung-Hoon, Kim Kihyun, Kim Jin Seok, Kim Seok Jin, Cheong Jung-Won, Kim Soo-Jeoong, Ahn Jae-Sook, Ahn Seo-Yeon, Yang Deok-Hwan, Kim Hyeoung-Joon, Lee Je-Jung

机构信息

Department of Haematology-Oncology, Chonnam National University Hwasun Hospital, Hwasun, Korea.

Division of Haematology-Oncology, Department of Medicine, Samsung Medical Centre, Sungkyunkwan University School of Medicine, Seoul, Korea.

出版信息

Br J Haematol. 2018 Jun;181(5):707-710. doi: 10.1111/bjh.14701. Epub 2017 May 3.

DOI:10.1111/bjh.14701
PMID:28466549
Abstract
摘要

相似文献

1
A prognostic scoring system for patients with multiple myeloma classified as stage II with the Revised International Staging System.一种针对采用修订国际分期系统被归类为II期的多发性骨髓瘤患者的预后评分系统。
Br J Haematol. 2018 Jun;181(5):707-710. doi: 10.1111/bjh.14701. Epub 2017 May 3.
2
[Analysis of the international staging system of multiple myeloma and its comparison with the DS and IFM staging system in 122 Chinese patients].[多发性骨髓瘤国际分期系统分析及其与122例中国患者的DS和IFM分期系统的比较]
Zhonghua Xue Ye Xue Za Zhi. 2008 Apr;29(4):217-21.
3
International staging system for multiple myeloma.多发性骨髓瘤国际分期系统
J Clin Oncol. 2005 May 20;23(15):3412-20. doi: 10.1200/JCO.2005.04.242. Epub 2005 Apr 4.
4
[Long-term survival and prognostic factors in stage II-III multiple myeloma treated with conventional chemotherapy].[接受传统化疗的II-III期多发性骨髓瘤的长期生存及预后因素]
Ann Med Interne (Paris). 1992;143(8):519-24.
5
Multiple myeloma staging based on the combination of beta-2-microglobulin and albumin: the role of albumin in the model.基于β2-微球蛋白和白蛋白联合检测的多发性骨髓瘤分期：白蛋白在该模型中的作用
Hematology. 2007 Dec;12(6):527-31. doi: 10.1080/10245330701384161.
6
Clinical utility of the Revised International Staging System in unselected patients with newly diagnosed and relapsed multiple myeloma.修订后的国际分期系统在未经选择的新诊断和复发多发性骨髓瘤患者中的临床应用。
Blood Cancer J. 2017 Feb 17;7(2):e528. doi: 10.1038/bcj.2017.13.
7
New staging systems can predict prognosis of multiple myeloma patients undergoing autologous peripheral blood stem cell transplantation as first-line therapy.新的分期系统可以预测接受自体外周血干细胞移植作为一线治疗的多发性骨髓瘤患者的预后。
Biol Blood Marrow Transplant. 2006 Aug;12(8):837-44. doi: 10.1016/j.bbmt.2006.04.006.
8
Evaluation of the Revised International Staging System (R-ISS) in Japanese patients with multiple myeloma.评估修订后的国际分期系统（R-ISS）在日本多发性骨髓瘤患者中的应用。
Ann Hematol. 2019 Jul;98(7):1703-1711. doi: 10.1007/s00277-019-03702-1. Epub 2019 May 2.
9
Revised International Staging System Applied to Real World Multiple Myeloma Patients.应用于真实世界多发性骨髓瘤患者的修订国际分期系统
Clin Lymphoma Myeloma Leuk. 2016 Sep;16(9):511-518. doi: 10.1016/j.clml.2016.06.001. Epub 2016 Jun 8.
10
Prognostic value of bone marrow angiogenesis in multiple myeloma: use of light microscopy as well as computerized image analyzer in the assessment of microvessel density and total vascular area in multiple myeloma and its correlation with various clinical, histological, and laboratory parameters.骨髓血管生成在多发性骨髓瘤中的预后价值：利用光学显微镜以及计算机图像分析仪评估多发性骨髓瘤中的微血管密度和总血管面积及其与各种临床、组织学和实验室参数的相关性。
Am J Hematol. 2006 Sep;81(9):649-56. doi: 10.1002/ajh.20639.

引用本文的文献

1
The quantitative parameters based on marrow metabolism derived from synthetic MRI: A pilot study of prognostic value in participants with newly diagnosed multiple myeloma.基于骨髓代谢的合成 MRI 定量参数：一项新诊断多发性骨髓瘤患者预后价值的初步研究。
Cancer Med. 2024 Apr;13(7):e7109. doi: 10.1002/cam4.7109.
2
A novel glycolysis-related gene signature for predicting the prognosis of multiple myeloma.一种用于预测多发性骨髓瘤预后的新型糖酵解相关基因特征。
Front Cell Dev Biol. 2023 Jun 2;11:1198949. doi: 10.3389/fcell.2023.1198949. eCollection 2023.
3
Identification and validation of a novel cuproptosis-related gene signature in multiple myeloma.
多发性骨髓瘤中一种新型铜死亡相关基因特征的鉴定与验证
Front Cell Dev Biol. 2023 Apr 20;11:1159355. doi: 10.3389/fcell.2023.1159355. eCollection 2023.
4
A Machine Learning Model to Predict Survival and Therapeutic Responses in Multiple Myeloma.机器学习模型预测多发性骨髓瘤的生存和治疗反应。
Int J Mol Sci. 2023 Apr 3;24(7):6683. doi: 10.3390/ijms24076683.
5
A prognostic model incorporating inflammatory cells and cytokines for newly diagnosed multiple myeloma patients.纳入炎症细胞和细胞因子的新型多发性骨髓瘤诊断预后模型。
Clin Exp Med. 2023 Oct;23(6):2583-2591. doi: 10.1007/s10238-023-00992-8. Epub 2023 Jan 13.
6
Progress of modern imaging modalities in multiple myeloma.多发性骨髓瘤的现代影像学进展。
Int J Hematol. 2022 Jun;115(6):778-789. doi: 10.1007/s12185-022-03360-6. Epub 2022 May 9.
7
Development of a new risk stratification system for patients with newly diagnosed multiple myeloma using R-ISS and F-FDG PET/CT.利用 R-ISS 和 F-FDG PET/CT 为新诊断的多发性骨髓瘤患者开发新的风险分层系统。
Blood Cancer J. 2021 Dec 1;11(12):190. doi: 10.1038/s41408-021-00577-2.
8
Endothelial activation and stress index (EASIX) is a reliable predictor for overall survival in patients with multiple myeloma.内皮细胞激活和应激指数（EASIX）是多发性骨髓瘤患者总体生存的可靠预测指标。
BMC Cancer. 2020 Aug 24;20(1):803. doi: 10.1186/s12885-020-07317-y.
9
Serum-free light chains combined with the Revised International Staging System could further distinguish the superior and inferior clinical outcome of multiple myeloma patients.血清游离轻链联合修订后的国际分期系统可进一步区分多发性骨髓瘤患者的预后优劣。
Ann Hematol. 2020 Aug;99(8):1779-1791. doi: 10.1007/s00277-020-04162-8. Epub 2020 Jun 27.
10
F-FDG PET/CT is useful for determining survival outcomes of patients with multiple myeloma classified as stage II and III with the Revised International Staging System.F-FDG PET/CT 对于使用修订后的国际分期系统（Revised International Staging System）分类为 II 期和 III 期的多发性骨髓瘤患者的生存结局的判断具有重要价值。
Eur J Nucl Med Mol Imaging. 2019 Jan;46(1):107-115. doi: 10.1007/s00259-018-4114-0. Epub 2018 Sep 5.